HLVX (HilleVax) Forward Dividend Yield % : 0.00% (As of May. 04, 2025)

View and export this data going back to 2022. Start your Free Trial

What is HilleVax Forward Dividend Yield %?

As of today (2025-05-04), the Forward Annual Dividend Yield of HilleVax is 0.00%.

As of today (2025-05-04), the Trailing Annual Dividend Yield of HilleVax is 0.00%.

HLVX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful Forward Dividend Yield % only.

HilleVax's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of HilleVax's Forward Dividend Yield %

For the Biotechnology subindustry, HilleVax's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HilleVax's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where HilleVax's Forward Dividend Yield % falls into.

Save Embed

;

Save Embed

;

HilleVax Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

HilleVax (NAS:HLVX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

HilleVax Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of HilleVax's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, Boston, MA, USA, 02118

Website

https://www.hillevax.com

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Executives

Robert Hershberg	director, officer: President and CEO	3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli	director, officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski	officer: Chief Medical Officer	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda	director	C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc.	10 percent owner	75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu	director	ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks	officer: CFO & Chief Business Officer	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130